What Drives 5-Amino-1MQ Pricing
5-amino-1MQ is a synthetic small molecule that inhibits nicotinamide N-methyltransferase (NNMT), an enzyme involved in cellular nicotinamide and methyl-group metabolism (Molecular metabolism, 2021). It is not a peptide, and it is not chemically related to GLP-1 receptor agonists or injectable weight-loss peptides, even though marketing sometimes lumps it into the same "metabolic supplement" category. It has no FDA-approved use for any condition, and it does not appear on FDA's 503A bulk drug substances list for compounding, which means pharmacies cannot legally compound it as a prescription product under that pathway (see the FDA bulk substances list). Everything sold today is a research chemical or unregulated supplement, and pricing exists entirely outside any FDA-set quality or cost framework.
Why does price vary so much between sellers?
Most of the variation traces back to four things that have nothing to do with biological effect:
Purity and identity testing. Some sellers publish certificates of analysis showing high-performance liquid chromatography (HPLC) or mass spectrometry results confirming the product actually contains 5-amino-1MQ at the stated concentration. This testing costs money and time, and sellers who do it tend to price higher. Sellers who skip it can price lower, but the buyer has no independent confirmation of what is in the vial or capsule. Pharmacokinetic characterization work, such as the rat plasma assay validation used in one bioavailability study (Journal of pharmaceutical and biomedical analysis, 2021), illustrates how much analytical work is required to even confirm a compound's identity and concentration accurately, and that is research-grade infrastructure most retail sellers do not replicate.
Synthesis and batch scale. Small-molecule NNMT inhibitors used in academic pharmacology research are typically synthesized in small, high-purity batches for lab use, not manufactured at consumer scale. Sellers marketing to consumers are usually buying from bulk chemical suppliers and repackaging, which changes the cost structure entirely and introduces more variability in sourcing quality.
Formulation choice. Products appear as raw powder, capsules, or sometimes dissolved liquid. Encapsulation and flavoring add cost. None of these formulation choices have been validated against each other for absorption or effect in humans, so paying more for a capsule does not mean paying for proven bioavailability.
Seller type and positioning. Chemical supply companies selling "for research use only" typically price differently than supplement brands marketing directly to consumers for weight management, even when the underlying material is similar. Consumer-facing brands add margin for marketing, packaging, and customer support, not for a different or better compound.
Does a higher price mean better evidence or more effect?
No, and this is the point where price and evidence diverge most sharply. Human clinical evidence for 5-amino-1MQ's effects on body weight, fat mass, or muscle is limited to essentially none in the sources available here. The supportive data are preclinical: NNMT inhibition reversed high-fat-diet-induced obesity in mice using selective small-molecule inhibitors (Biochemical pharmacology, 2018), and a separate small molecule inhibitor targeting NNMT showed effects on metabolic markers in animal models (Scientific reports, 2018). NNMT itself is mechanistically linked to obesity and type 2 diabetes pathways in review literature (BioMed research international, 2021), and more recent work continues to explore NNMT inhibition as a therapeutic target for metabolic syndrome (Frontiers in pharmacology, 2024) and metabolic dysfunction in obesity models (Diabetes, obesity & metabolism, 2024). None of this is human trial evidence, and none of it establishes a dose, formulation, or price point that correlates with outcome in people. A seller charging more per milligram is not charging more because of stronger human evidence, because that evidence does not currently exist at a level that would support a claim like that. For more on what the animal data actually show and where it stops, see our review of 5-amino-1MQ weight-loss evidence and the mechanism overview.
Is a cheaper alternative like berberine a fair price comparison?
Berberine and 5-amino-1MQ are sometimes marketed side by side as "metabolic support" compounds, but they act through different pathways and have very different evidence bases; berberine has a longer history of human studies, while 5-amino-1MQ's human data are essentially absent from the literature reviewed here. Comparing them on price alone, without accounting for the underlying evidence gap, is not a meaningful economic comparison. A detailed head-to-head is covered in 5-amino-1MQ vs berberine.
What should a buyer actually be paying for?
Given the absence of FDA oversight, the honest framing is that a buyer is paying for confidence in identity and purity, not for a validated therapeutic effect. That distinction matters because it changes what "value" means here entirely.
A framework for reading a 5-amino-1MQ price tag
Use this to separate what a price actually buys from what it implies:
| Price signal | What it plausibly buys | What it does NOT prove |
|---|---|---|
| Published third-party certificate of analysis (HPLC/MS) | Some confirmation of identity and stated concentration | Sterility, absence of contaminants beyond what was tested, or human efficacy |
| "Pharmaceutical grade" or "research grade" labeling with no linked document | Marketing language | Nothing verifiable on its own |
| Premium capsule or liquid formulation | Convenience, taste, shelf stability | Better absorption or effect versus raw powder, since no human bioavailability comparison exists |
| Higher price from a long-established chemical supplier | Possibly more consistent batch sourcing | Regulatory approval or clinical validation, since neither exists for this compound |
| Discounted bulk pricing from a new or unlisted seller | Lower cost per unit | Product identity, purity, or that the batch matches any prior batch |
| Any price point | Nothing about human safety or efficacy, since that has not been established in trials | Compliance with any FDA quality standard, since 5-amino-1MQ is not FDA-approved and not on the 503A bulk list |
If a listing cannot produce a batch-specific certificate of analysis on request, price is not a useful proxy for quality at all, regardless of whether it is high or low.
What is established, what is plausible, and what is not established
Established: 5-amino-1MQ is a small-molecule NNMT inhibitor with a defined mechanism studied in enzymatic and animal models (Molecular metabolism, 2021; Biochemical pharmacology, 2018). It has no FDA-approved indication and is not on the 503A bulk substances list.
Plausible but unproven: that NNMT inhibition could translate into meaningful metabolic effects in humans, based on the animal and mechanistic literature (BioMed research international, 2021; Diabetes, obesity & metabolism, 2024).
Not established: any human dose-response relationship, any validated formulation or bioavailability standard for consumer products, and any correlation between price and biological effect. Buyers should treat pricing as a purity and sourcing question, not an efficacy question, and should check current regulatory status before purchase since oversight can shift; see the FDA status page and the FDA Peptide Status Tracker for updates. Anyone considering use should also review dosing claims and side effects and safety, and discuss it with a physician rather than relying on seller marketing, particularly given the near-total absence of human safety data.
If unexpected symptoms occur after using any unregulated research chemical, including unexplained rash, chest pain, difficulty breathing, or severe gastrointestinal distress, seek urgent medical care rather than waiting to identify the cause.